LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Elenco Azioni・iRhythm Technologies Inc

iRhythm Technologies Inc

Chiusa

SettoreSettore sanitario

118.24 1.21

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

115.61

Massimo

119.65

Metriche Chiave
By Trading Economics
Entrata	-20M -14M
Vendite	-9.5M 199M
EPS	-0.35
Margine di Profitto	-6.988
Dipendenti	2,400
EBITDA	-21M -5.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+53.97% upside

Dividendi
By Dow Jones
Utili prossimi	30 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-299M 3.8B
Apertura precedente	117.03
Chiusura precedente	118.24

Notizie sul Sentiment di mercato

By Acuity

50%

150 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

104.78 / 137.91 Supporto e resistenza

iRhythm Technologies Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2026, 22:50 UTC

Utili

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mag 2026, 22:49 UTC

Utili

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mag 2026, 22:32 UTC

Utili

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mag 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mag 2026, 22:57 UTC

Discorsi di Mercato

Utili

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mag 2026, 22:26 UTC

Utili

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mag 2026, 22:25 UTC

Utili

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mag 2026, 22:25 UTC

Utili

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mag 2026, 22:24 UTC

Utili

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mag 2026, 22:23 UTC

Utili

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mag 2026, 22:23 UTC

Utili

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mag 2026, 22:19 UTC

Utili

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mag 2026, 22:14 UTC

Utili

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mag 2026, 22:14 UTC

Utili

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mag 2026, 22:13 UTC

Utili

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mag 2026, 22:12 UTC

Utili

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mag 2026, 22:12 UTC

Utili

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mag 2026, 22:11 UTC

Utili

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mag 2026, 22:11 UTC

Utili

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mag 2026, 22:10 UTC

Utili

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mag 2026, 22:09 UTC

Utili

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mag 2026, 22:09 UTC

Utili

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mag 2026, 22:08 UTC

Utili

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mag 2026, 22:07 UTC

Utili

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mag 2026, 22:06 UTC

Utili

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mag 2026, 22:06 UTC

Utili

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mag 2026, 22:05 UTC

Utili

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Confronto tra pari

Modifica del prezzo

iRhythm Technologies Inc Previsione

Obiettivo di Prezzo

By TipRanks

53.97% in crescita

Previsioni per 12 mesi

Media 179.9 USD 53.97%

Alto 255 USD

Basso 147 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per iRhythm Technologies Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 13 che hanno fornito valutazioni azionarie a iRhythm Technologies Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

104.78 / 137.91Supporto e resistenza

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

150 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo iRhythm Technologies Inc

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.